SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to initial alarm from a Stocktwits pricing glitch and concerns over geopolitical events impacting South Korean memory chip rivals, though many in the community argue these events could actually benefit $MU given its limited exposure and strong demand for its AI-driven HBM products ahead of strong earnings expectations.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amidst significant market volatility fueled by escalating geopolitical tensions in the Middle East, which are driving up oil prices and triggering circuit breakers in global markets. The community is sharply divided between those advocating to "buy the dip" and others expressing frustration over perceived market manipulation and the sustainability of current price action, even as government intervention aims to secure energy flows.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF is trending as breaking reports of Iran's Supreme Leader being killed and subsequent negotiation offers ignite intense market volatility. The community is sharply divided between anticipating a short squeeze or a broader downturn, with ongoing concerns about oil prices and geopolitical instability driving widespread debate.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is highly volatile amid escalating Middle East tensions, fueling fears of rising oil prices and inflation, alongside market uncertainty over new tariffs and AI's impact on tech. The community is sharply divided between those bracing for further declines and aggressive dip-buyers anticipating a significant rally or short squeeze in the leveraged tech ETF.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is generating significant debate ahead of its imminent earnings report, as frustrated investors grapple with its continued decline to new 52-week lows, while others point to deep undervaluation and strong fundamentals amidst intense sector competition and geopolitical concerns.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing a surge in attention due to escalating geopolitical tensions highlighting the critical role of drone technology in modern warfare. Community discussion is buzzing with expectations of a short squeeze and imminent results from the Drone Dominance Gauntlet program, which could further solidify the company's position in defense solutions.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

DJIA is trending amidst heightened geopolitical tensions, including ongoing developments in the Middle East and tariff discussions, which are driving broad market volatility. Community sentiment is sharply divided, with some expressing optimism for market resilience and potential gains, while others voice concerns about a broader economic downturn and market vulnerability.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing a tug-of-war in sentiment as traders weigh geopolitical tensions in the Middle East and upcoming Nvidia earnings against ongoing strong AI demand for semiconductors. The community is sharply divided, with some actively "buying the dip" and others warning of a significant pullback due to leveraged ETF decay and broader market uncertainty.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is a hot topic following an earnings call that showcased robust ANKTIVA revenue growth and plans for immediate global product shipments, sparking community debate between long-term optimism for a cancer cure and short-term investor disappointment over financial guidance amidst active short-seller sentiment.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is trending as South Korea's market experienced a significant decline, triggering circuit breakers amid surging oil and LNG prices fueled by geopolitical tensions, which led to a massive sell-off in key semiconductor holdings like Samsung and SK Hynix; the community is actively debating whether this represents an excessive correction and a prime buying opportunity or a sign of an over-extended market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CrowdStrike, Mobix Labs, Micron Technology, Target And Moderna: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks finished Tuesday lower as mounting tensions in the conflict with Iran weighed on sentiment. The Dow Jones Industrial Average slid 0.8% to 48,501.27.read more...

Moderna Stock Jumps 10% After Hours: Here's Why

Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement.read more...

Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus

(RTTNews) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary of Roivant...

<ul class="summary-bullets"><li>Moderna said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.&nbsp;</li><li>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li><li>The remaining $1.3 billion payout is subject to further litigation.</li></ul>Shares of vaccine maker Moderna (MRNA) rallied after hours on Tuesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma.The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5178901572623640&amp;symbol=MRNA">said</a> that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.<a href="https://stocktwits.com/symbol/ABUS">Shares of Arbutus</a> fell 8% after hours at the time of writing while shares of Genevant’s parent <a href="https://stocktwits.com/symbol/ROIV">Roivant Sciences</a> gained nearly 1%. Meanwhile, shares of MRNA rallied 11%.<h2 class="st-heading-2">Settlement Agreement</h2>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion."Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future," said Moderna CEO Stéphane Bancel.The company now expects to end the year with $4.5 to $5.0 billion in cash and cash equivalents. The total projected liquidity available to the company at the end of 2026 will be $5.4 to $5.9 billion, it added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 65% over the past 12 months. Meanwhile, ABUS and ROIV added 37% and 174%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/autozone-shares-dive-post-earnings-but-wells-fargo-sees-buying-opportunity/cZdeYkuRIPt">AutoZone Shares Dive Post-Earnings But Wells Fargo Sees A Buying Opportunity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccine Spikevax.

Equity

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccine Spikevax.


Top Biotech Stocks To Watch Now - March 3rd

Danaher, Moderna, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop...

Biotech Stocks To Follow Today - March 2nd

Danaher, Moderna, and ImmunityBio are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop, and...

MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot

Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.

Promising Biotech Stocks To Research - March 1st

Danaher, Vertex Pharmaceuticals, Moderna, argenex, United Therapeutics, ImmunityBio, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Biotech Stocks To Keep An Eye On - February 28th

Danaher, Vertex Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop...

This Is What Whales Are Betting On Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

Moderna settled its worldwide COVID vaccine patent dispute with Arbutus and Genevant for $2.25 billion, securing its infectious disease portfolio from future royalties.

European regulators endorsed the company's first-to-market COVID-19 and influenza combination vaccine, signaling a significant validation and growth catalyst.

Excitement builds around the oncology pipeline, with 5-year data showing sustained efficacy for the personalized cancer vaccine partnered with Keytruda.

Aggressive price targets are emerging, with many expecting a significant short squeeze to push the stock toward $75-100+ after recent positive catalysts.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc